India’s Pharma Sector: World No.3 in Volume, 11th by Value
1 min read
India’s pharma industry stands tall globally, clinching third place in production volume and 11th in monetary value, supported by 3,000 companies and 10,500 manufacturing sites.
The $60 billion domestic market forecasts $130 billion by 2030. Economic Survey 2025-26 notes Rs 4.72 lakh crore turnover in FY 2024-25, with exports averaging 7 percent growth yearly for a decade.
As generics giant with 20 percent world supply—producing 60,000 variants in 60 categories—India excels due to strong infrastructure, export momentum, investments, and government initiatives reducing imports and fortifying global stance.
USFDA nods to most foreign plants highlight quality; 500 API makers claim 8 percent global pie. Vaccines prowess includes 60 percent UNICEF, 40-70 percent DPT/BCG global, 90 percent WHO measles supply.
EU, UK, NZ trade ties will spur new opportunities in markets, funding, employment. FY 2024-25 exports at $30.5 billion dwarf 2000-01’s $1.9 billion by 16 times. Affordability, R&D, regulations have uplifted health services, earning India enduring trust worldwide.
